Who Are We ?
We are ISOBiotech, a rapidly emerging Australian start-up revolutionising the field of molecular diagnostics. Backed by nearly two decades of deep expertise, we have developed a proprietary isothermal amplification technology—Isothermal PCR Amplification (IPA™)—that delivers rapid, accurate, and scalable detection of any known infectious disease.
At the core of our innovation is IPA™, a novel amplification chemistry that pairs seamlessly with our compact, easy-to-use diagnostic platform, the RapidDetector™. Together, they enable fast, reliable, and decentralized testing, without the need for complex instrumentation or laboratory infrastructure.
We are actively seeking strategic investment to accelerate product development, expand our market reach, and scale manufacturing. With a strong foundation, an innovative platform, and a clear path to commercialisation, we are positioned to become a global leader in next-generation molecular diagnostics.
Our Products
Driven by a multidisciplinary team of seasoned scientists, engineers, and healthcare professionals and supported by academic and clinical collaborators, we are building a scalable portfolio of diagnostic products centred on our IPA™ and RapidDetector™ platforms, as listed below:
Each product is designed to meet ISO13485:2016 international standards for medical device manufacturing process and is backed by rigorous verification studies.
Our In Vitro Diagnostic (IVD) solutions are designed to transform the way infectious diseases are detected, monitored, and managed, by empowering clinicians and public health systems with tools that are accurate, affordable, and accessible. Our technology is well-suited to meet global demands for point-of-care diagnostics, especially in resource-limited settings or during health emergencies such as epidemics and pandemics.
Why Invest In Us ?
Market Potential
The global IVD market is projected to exceed $100 billion by 2030, driven by demand for rapid diagnostics and personalized medicine.
Proprietary Technology
Our IPA™ technology coupled with the RapidDetector™ platform integrates unique biomarkers, excellent in-vivo catalytic biomarkers and smart detection systems for unmatched sensitivity and specificity.
Clinical Relevance
Designed for real-world use in hospitals, clinics, pen-side and remote care settings – our products meet urgent diagnostic needs.
Expert Team
Led by industry experts and supported by advisors from academic institutions, medical/pathology laboratories and feedback from users.
Investment Opportunities
We are inviting strategic investors to partner with us at a pivotal moment in our growth journey. With a breakthrough diagnostic platform, strong IP, and a highly experienced team, we are uniquely positioned to capitalize on a rapidly expanding global market for infectious disease diagnostics.
Your investment will directly accelerate:
- Final-stage product development, clinical validation, and regulatory approvals including TGA, FDA, and CE marking for enhanced market reach
- Scale-up of manufacturing operations to meet global demand
- Global marketing and distribution
Whether you’re a venture capitalist, angel investor, or institutional fund, we offer flexible investment structures and a clear, well-defined path to ROI: driven by unmet clinical needs, scalable technology, and strong commercial potential.
Partner With Us
Join us in revolutionising diagnostics and shaping the future of healthcare. Together, we can deliver smarter, faster, and more reliable testing solutions to millions worldwide. Now is the time to invest in a diagnostic platform that combines scientific innovation with real-world impact.
Contact Us
Interested in learning more or scheduling a pitch meeting? Reach out to our team at: invest@isobiotech.com.au, or lodge an enquiry!